How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects 30 to 40% of the population globally and is increasingly considered the most common liver disease. Patients with type 2 diabetes, obesity, and cardiovascular diseases are at especially increased risk for NAFLD. Although most patients with NAFLD do not have progressive liver disease, some patients progress to cirrhosis, liver cancer, and liver mortality. Given the sheer number of patients with NAFLD, the burden of disease is enormous. Despite this large and increasing burden, identification of NAFLD patients at risk for progressive liver disease in the primary care and diabetology practice settings remains highly suboptimal. In this review, our aim is to summarize a stepwise approach to risk stratify patients with NAFLD which should help practitioners in their management of patients with NAFLD.

Keywords

nonalcoholic fatty liver disease - risk stratification - advanced disease - noninvasive tests - primary care

Publikationsverlauf

Artikel online veröffentlicht:
06. Juli 2023

• References

• 1 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77 (04) 1335-1347
• 2 Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022; 56 (06) 942-956
• 3 Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: review of management for primary care providers. Mayo Clin Proc 2022; 97 (09) 1700-1716
• 4 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67 (01) 328-357
• 5 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev 2020; 41 (01) bnz009
• 6 Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore) 2018; 97 (13) e0214
• 7 Lomonaco R, Godinez Leiva E, Bril F. et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 2021; 44 (02) 399-406
• 8 Younossi Z, Stepanova M, Ong JP. et al; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019; 17 (04) 748-755.e3
• 9 Younossi ZM, Shabeeb R, Harring M. et al. The portrait of adult liver transplant recipients in the United States from 2002-2020. J Hepatol 2022; 77 (01) 810-811
• 10 Kanwal F, Shubrook JH, Younossi Z. et al. Preparing for the NASH Epidemic: a call to action. Gastroenterology 2021; 161 (03) 1030-1042.e8
• 11 Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59 (06) 2188-2195
• 12 Cusi K, Isaacs S, Barb D. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28 (05) 528-562
• 13 Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014; 63 (02) 161-167
• 14 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28 (Suppl. 01) 68-76
• 15 Younossi ZM, Stepanova M, Rafiq N. et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53 (06) 1874-1882
• 16 Dulai PS, Singh S, Patel J. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017; 65 (05) 1557-1565
• 17 Taylor RS, Taylor RJ, Bayliss S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158 (06) 1611-1625.e12
• 18 Ekstedt M, Hagström H, Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (05) 1547-1554
• 19 Angulo P, Kleiner DE, Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149 (02) 389-97.e10
• 20 Younossi ZM, Pham H, Felix S. et al. Identification of high-risk patients with nonalcoholic fatty liver disease using noninvasive tests from primary care and endocrinology real-world practices. Clin Transl Gastroenterol 2021; 12 (04) e00340
• 21 Shaheen AA, Riazi K, Medellin A. et al. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020; 8 (02) E370-E376
• 22 Goodman ZD. Role of liver biopsy in clinical trials and clinical management of nonalcoholic fatty liver disease. Clin Liver Dis 2023; 27 (02) 353-362
• 23 Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol 2016; 10 (01) 63-71
• 24 Chow KW, Futela P, Saharan A, Saab S. Comparison of guidelines for the screening, diagnosis, and noninvasive assessment of nonalcoholic fatty liver disease. J Clin Exp Hepatol 2023. Doi: 10.1016/j.jceh.2023.01.016
• 25 Lazarus JV, Castera L, Mark HE. et al. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. JHEP Rep Innov Hepatol 2022; 5 (01) 100596
• 26 Henry L, Eberly KE, Shah D, Kumar A, Younossi ZM. Noninvasive tests used in risk stratification of patients with nonalcoholic fatty liver disease. Clin Liver Dis 2023; 27 (02) 373-395
• 27 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020; 3 (04) e00127
• 28 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol 2022; 76 (06) 1362-1378
• 29 Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020; 9 (04) 1005
• 30 Limanond P, Raman SS, Lassman C. et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004; 230 (01) 276-280
• 31 Fazel R, Krumholz HM, Wang Y. et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361 (09) 849-857
• 32 Idilman IS, Keskin O, Celik A. et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol 2016; 57 (03) 271-278
• 33 Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y) 2012; 8 (09) 605-607
• 34 Roulot D, Costes JL, Buyck JF. et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60 (07) 977-984
• 35 Wong VWS, Vergniol J, Wong GLH. et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107 (12) 1862-1871
• 36 Nowotny F, Schmidberger J, Schlingeloff P, Binzberger A, Kratzer W. Comparison of point and two-dimensional shear wave elastography of the spleen in healthy subjects. World J Radiol 2021; 13 (05) 137-148
• 37 Liu H, Fu J, Hong R, Liu L, Li F. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis. PLoS One 2015; 10 (07) e0127782
• 38 Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res 2015; 45 (02) 142-151
• 39 Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259 (03) 749-756
• 40 Loomba R, Wolfson T, Ang B. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60 (06) 1920-1928
• 41 Rossi E, Adams LA, Ching HL, Bulsara M, MacQuillan GC, Jeffrey GP. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clin Chem Lab Med 2013; 51 (05) 1107-1114
• 42 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (04) 1072-1078
• 43 Yang M, Xu D, Liu Y. et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One 2015; 10 (06) e0131664
• 44 Bedogni G, Bellentani S, Miglioli L. et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
• 45 Lee JH, Kim D, Kim HJ. et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42 (07) 503-508
• 46 Otgonsuren M, Estep MJ, Hossain N. et al. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 2014; 29 (12) 2006-2013
• 47 Harrison SA, Ratziu V, Boursier J. et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020; 5 (11) 970-985
• 48 Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD Score. Gut Liver 2013; 7 (03) 323-328
• 49 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol 2015; 343828
• 50 Tapper EB, Krajewski K, Lai M. et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf) 2014; 2 (04) 276-280
• 51 Adams LA, George J, Bugianesi E. et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26 (10) 1536-1543
• 52 Armstrong MJ, Houlihan DD, Bentham L. et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56 (01) 234-240
• 53 Vallet-Pichard A, Mallet V, Nalpas B. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46 (01) 32-36
• 54 Wada T, Zeniya M. Background of the FIB-4 index in Japanese non-alcoholic fatty liver disease. Intern Med 2015; 54 (02) 127-132
• 55 Younes R, Caviglia GP, Govaere O. et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 2021; 75 (04) 786-794
• 56 Poynard T, Morra R, Halfon P. et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40
• 57 Sharma C, Cococcia S, Ellis N, Parkes J, Rosenberg W. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol 2021; 36 (07) 1788-1802
• 58 Guha IN, Parkes J, Roderick P. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (02) 455-460
• 59 Arora A, Sharma P. Non-invasive diagnosis of fibrosis in non-alcoholic fatty liver disease. J Clin Exp Hepatol 2012; 2 (02) 145-155
• 60 Vali Y, Lee J, Boursier J. et al; LITMUS Systematic Review Team(†). Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 2020; 73 (02) 252-262
• 61 Newsome PN, Sasso M, Deeks JJ. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020; 5 (04) 362-373
• 62 Noureddin M, Truong E, Gornbein JA. et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol 2022; 76 (04) 781-787
• 63 Ajmera V, Kim BK, Yang K. et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology 2022; 163 (04) 1079-1089.e5
• 64 Pennisi G, Enea M, Pandolfo A. et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol 2023; 21 (05) 1293-1302.e5
• 65 Loomba R, Huang DQ, Sanyal AJ. et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 2023; 72 (03) 581-589
• 66 Younossi ZM, Corey KE, Alkhouri N. et al; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020; 52 (03) 513-526
• 67 Kanwal F, Shubrook JH, Adams LA. et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021; 161 (05) 1657-1669
• 68 Younossi Z, Alkhouri N, Cusi K. et al. A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2023; 57 (03) 304-312
• 69 Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken) 2021; 17 (01) 23-28
• 70 Jacobson IM, Wong VWS, Castera L. et al. Expert panel consensus on clinical assertion statements describing noninvasive tools for diagnosing nonalcoholic steatohepatitis. J Clin Gastroenterol 2023; 57 (03) 253-264
• 71 Kugelmas M, Noureddin M, Gunn N. et al. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. Liver Int 2023; 43 (05) 964-974